Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. METHODS: We randomly assigned patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had or did not have brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine. The primary end point was progression-free survival among the first 480 patients who underwent randomization. Secondary end points, assessed in the total population (612 patients), included overall survival, progression-free survival among patients with brain metastases, confirmed objective response rate, and safety. RESULTS: Progression-free survival at 1 year was 33.1% in the tucatinib-combination group and 12.3% in the placebo-combination group (hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.42 to 0.71; P<0.001), and the median duration of progression-free survival was 7.8 months and 5.6 months, respectively. Overall survival at 2 years was 44.9% in the tucatinib-combination group and 26.6% in the placebo-combination group (hazard ratio for death, 0.66; 95% CI, 0.50 to 0.88; P = 0.005), and the median overall survival was 21.9 months and 17.4 months, respectively. Among the patients with brain metastases, progression-free survival at 1 year was 24.9% in the tucatinib-combination group and 0% in the placebo-combination group (hazard ratio, 0.48; 95% CI, 0.34 to 0.69; P<0.001), and the median progression-free survival was 7.6 months and 5.4 months, respectively. Common adverse events in the tucatinib group included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fatigue, and vomiting. Diarrhea and elevated aminotransferase levels of grade 3 or higher were more common in the tucatinib-combination group than in the placebo-combination group. CONCLUSIONS: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This was achieved at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of grade ≥3, but did not lead to frequent treatment discontinuation.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
In the citing paper
“Tucatinib, a highly selective inhibitor of the HER2 tyrosine kinase, used in combination with capecitabine and trastuzumab in a population of ABC patients pretreated with trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1), demonstrated improvement of PFS (median 7.8 months versus 5.6 months, HR 0.54; 95% CI 0.42-0.71, P < 0.001) and OS (median 21.9 months versus 17.4 months, HR 0.66; 95% CI”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,845
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationBendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Self-citationLin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Self-citationOwens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Research works printed but not linked: 1
- Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res 2009;69:1795-1795. abstract.
Cited by
Items 301–400 of 1,000
Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond
Kim, I.-H. (2023) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2024.24.e6 · Cited by 31
“Tucatinib, an oral RTK inhibitor, is being studied for its high selectivity for the kinase domain of HER2, while having a minimal impact on EGFR inhibition [71].”
BackgroundZhao, L., Xing, Y. T., Liu, C., Ma, S., Huang, W., Cheng, Z., & Zhao, J. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01803-y · Cited by 26
“Tc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial Background Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 15–20% of breast cancers [1].”
BackgroundUse of new and emerging cancer drugs: what the cardiologist needs to know
Fabiani, I., Chianca, M., Aimo, A., Emdin, M., Dent, S. F., Fedele, A., Cipolla, C. M., & Cardinale, D. M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae161 · Cited by 27
Freedman, R. A., Heiling, H., Li, T., Trapani, D., Tayob, N., Smith, K. L., Davis, R., Pereslete, A., DeMeo, M. K., Cotter, C., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.07.245 · Cited by 26
Self-citationHeterogeneity and vascular permeability of breast cancer brain metastases
Babak, M. V., Zalutsky, M. R., & Balyasnikova, I. V. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.012 · Cited by 31
Brain metastases in metastatic cancer: a review of recent advances in systemic therapies
Steindl, A., & Berghoff, A. S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1851200 · Cited by 26
Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis
Nasrazadani, A., & Brufsky, A. (2020) · Future Oncology · doi:10.2217/fon-2019-0719 · Cited by 25
Battisti, N. M. L., Rogerson, F., Lee, K. C. L., Shepherd, S. T. C., Mohammed, K., Turner, N. C., McGrath, S., Okines, A. F. C., Parton, M., Johnston, S. R. D., et al. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100188 · Cited by 25
Self-citationPrevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer
Månsson‐Broberg, A., Geisler, J., TUOHINEN, S. S., Skyttä, T., Hrafnkelsdóttir, Þ. J., Nielsen, K. M., Hedayati, E., Omland, T., Offersen, B. V., Lyon, A. R., et al. (2020) · Current Heart Failure Reports · doi:10.1007/s11897-020-00486-8 · Cited by 28
Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer
Yang, Z., Wang, W., Wang, X., & Qin, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.741451 · Cited by 27
Wooster, M. E., McGuinness, J. E., Fenn, K. M., Singh, V., Franks, L. E., Lee, S. Y., Cieremans, D. A., Lassman, A. B., Hershman, D. L., Crew, K. D., et al. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.11.002 · Cited by 25
Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature
Ozaki, Y., Miura, S., Oki, R., Morikawa, T., & Uchino, K. (2021) · Cancers · doi:10.3390/cancers14010196 · Cited by 33
Ferraro, E., Singh, J. C., Patil, S., Razavi, P., Modi, S., Chandarlapaty, S., Barrio, A. V., Malani, R., Mellinghoff, I. K., Boire, A. A., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00380-7 · Cited by 26
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases
Tripathy, D., Tolaney, S. M., Seidman, A. D., Anders, C. K., Ibrahim, N. K., Rugo, H. S., Twelves, C., Dieras, V. C., Müller, V., Du, Y., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0514 · Cited by 25
Self-citationLeveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
Wilcox, J. A., & Boire, A. A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00975-5 · Cited by 28
“0 months), when used in combination with trastuzumab and capecitabine in those with stable or active brain metastases [35, 127].”
MethodGeng, W., Thomas, H., Chen, Z., Yan, Z., Zhang, P., Zhang, M., Huang, W., Ren, X., Wang, Z., Ding, K., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176725 · Cited by 28
Personalized treatment approach for HER2-positive metastatic breast cancer
Pandey, P., Chaudhary, R., Tripathi, D., Lavudi, K., Dua, K., Weinfeld, M., Lavasanifar, A., & Rajinikanth, P. S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02504-4 · Cited by 30
“The tucatinib, capecitabine, and trastuzumab combination is also a promising treatment for HER2-positive MBC, showing improved overall survival in previously treated patients and ongoing evaluation in earlier stages [7].”
Aljuhani, A., Nafie, M. S., Albujuq, N. R., Alsehli, M., Bardaweel, S. K., Darwish, K. M., Al‐Raqa, S. Y., Aouad, M. R., & Rezki, N. (2025) · RSC Advances · doi:10.1039/d4ra07540d · Cited by 25
Linehan, A., Fitzpatrick, O. M., & Morris, P. G. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s245024 · Cited by 27
“4 months for patients treated with placebo.(10) Another novel agent in this setting is the Fc engineered anti-HER2 monoclonal antibody margetuximab.”
Fetal sex determination by ultrasound scan in the second and third trimesters.
Plattner, G., Renner, W. R., Went, J., Beaudette, L., & Viau, G. (1983) · PubMed · Cited by 25
Leptomeningeal metastases: the future is now
Lukas, R. V., Thakkar, J. P., Cristofanilli, M., Chandra, S., Sosman, J. A., Patel, J. D., Kumthekar, P., Stupp, R., & Lesniak, M. S. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03924-2 · Cited by 25
“9% compared to 0% in the control arm [64].”
BackgroundChallenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD)
Ferguson, S. D., Fomchenko, E. I., Guerrieri, R. A., & Oliva, I. C. G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.800053 · Cited by 27
“However, this trial did not include LMD patients (69).”
BackgroundNakajima, H., Harano, K., Nakai, T., Kusuhara, S., Nakao, T., Funasaka, C., Kondoh, C. N., Matsubara, N., Naito, Y., Hosono, A., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.01.002 · Cited by 24
“Nonetheless, the clinical benefits of T-DXd in this study appeared to be superior to those of chemotherapy plus anti-HER2 targeted agents administered after T-DM1, before the approval of T-DXd [30], and to those of recent phase 3 trials of new agents such as tucatinib and margetuximab [31,32].”
Wuerstlein, R., Ellis, P., Montemurro, F., Torres, A. A., Delaloge, S., Zhang, Q., Wang, X., Wang, S., Shao, Z., Li, H., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100561 · Cited by 26
Xie, X., Zhang, Q., Huang, J., Chen, L., Lan, X., Bai, X., Song, L., Xiong, S.-L., Guo, S., & Du, C. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06770-6 · Cited by 24
“1 3 visceral-metastases were not available in HER2CLIMB trial [19].”
BackgroundAltena, R., Tzortzakakis, A., af Burén, S., Tran, T. A., Frejd, F. Y., Bergh, J. C. S., & Axelsson, R. (2023) · EJNMMI Research · doi:10.1186/s13550-023-00995-2 · Cited by 29
Geurts, V. C. M., Voorwerk, L., Balduzzi, S., Salgado, R., de Vijver, K. K. V., van Dongen, M. G. J., Kemper, I., Mandjes, I. A. M., Heuver, M., Sparreboom, W., et al. (2023) · The Breast · doi:10.1016/j.breast.2023.06.007 · Cited by 24
Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)
Xu, B., & Ma, F. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.12.001 · Cited by 30
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer
Momeny, M., Tienhaara, M., Sharma, M., Chakroborty, D., Varjus, R., Takala, I., Merisaari, J., Padzik, A., Vogt, A., Paatero, I., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00088-0 · Cited by 27
Ren, D., Cheng, H., Wang, X., Vishnoi, M., Teh, B. S., Rostomily, R., Chang, J. C., Wong, S. T. C., & Zhao, H. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936151 · Cited by 29
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer
Agostinetto, E., Debien, V., Marta, G. N., Lambertini, M., Piccart, M. J., & de Azambuja, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13535 · Cited by 27
Marquez-Palencia, M., Herrera, L. R., Parida, P. K., Ghosh, S., Kim, K., Das, N. M., Ericsson, P. I. G., Sanders, M. E., Mobley, B. C., Diegeler, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1459 · Cited by 23
JAC1 suppresses proliferation of breast cancer through the JWA/p38/SMURF1/HER2 signaling
Ren, Y., Chen, D., Chen, J., Zhai, Z., Li, A., Liang, Y., Yin, Y., 束永前, & Zhou, J. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00426-y · Cited by 24
Asgari-Karchekani, S., Aryannejad, A., Mousavi, S. A., Shahsavarhaghighi, S., & Tavangar, S. M. (2022) · Medical Oncology · doi:10.1007/s12032-022-01817-6 · Cited by 24
An Insight into Molecular Targets of Breast Cancer Brain Metastasis
Kaleem, M., Dalhat, M. H., Azmi, L., Asar, T. O., Ahmad, W., Alghanmi, M. S., Almostadi, A., Zughaibi, T. A., & Tabrez, S. S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911687 · Cited by 24
“Tucatinib is a tyrosine kinase inhibitor, highly selective for the HER2 protein and can slightly inhibit the epidermal growth factor receptor [132].”
BackgroundFrenel, J., Zeghondy, J., Guérin‐Charbonnel, C., Mailliez, A., Volant, E., Poumeaud, F., Patsouris, A., Arnedos, M., Bailleux, C., Cabal, J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.4435 · Cited by 23
Self-citationDevelopment and biological assessment of MMAE-trastuzumab antibody–drug conjugates (ADCs)
Yaghoubi, S., Gharibi, T., Karimi, M. H., Nezhad, M. S., Seifalian, A. M., Tavakkol, R., Bagheri, N., Dezhkam, A., & Abdollahpour‐Alitappeh, M. (2020) · Breast Cancer · doi:10.1007/s12282-020-01153-5 · Cited by 23
Li, Y., Li, Q., Mo, H., Guan, X., Lin, S., Wang, Z., Chen, Y., Zhang, Y., Zhang, D., Chen, S., et al. (2020) · The Breast · doi:10.1016/j.breast.2020.11.021 · Cited by 23
Current Development of Glioblastoma Therapeutic Agents
Wang, Z., Peet, N. P., Zhang, P., Jiang, Y., & Rong, L. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0159 · Cited by 23
“Even more interesting, in patients with HER2positive breast cancer with BM, the addition of tucatinib to trastuzumab and capecitabine treated patients was reported to produce better progression-free survival and overall survival (33, 34).”
BackgroundThill, M., Lüftner, D., Kolberg‐Liedtke, C., Albert, U., Banys‐Paluchowski, M., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Fallenberg, E. M., et al. (2022) · Breast Care · doi:10.1159/000524789 · Cited by 24
Self-citationEscalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer
File, D. M., Curigliano, G., & Carey, L. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100023 · Cited by 22
Self-citationGampenrieder, S. P., Castagnaviz, V., Rinnerthaler, G., & Greil, R. (2020) · Cancer Management and Research · doi:10.2147/cmar.s235121 · Cited by 23
Self-citationDai, M., Feng, Y. H., Chen, S. W., Masuda, N., Yau, T. C. C., Chen, S. T., Lu, Y., Yap, Y. S., Ang, P., Chu, S. C., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06313-5 · Cited by 22
Cao, Y., Li, Y., Liu, R., Zhou, J., & Wang, K. (2023) · Cancers · doi:10.3390/cancers15092568 · Cited by 29
“For example, lapatinib is EGFR/HER2 TKI [21], neratinib is a pan-HER TKI [22], and tucatinib is the selective HER2-targeted TKI [23].”
InfluentialMargetuximab in HER2-positive metastatic breast cancer
Gradishar, W. J., O'Regan, R. M., Rimawi, M. F., Nordstrom, J. L., Rosales, M. K., & Rugo, H. S. (2023) · Future Oncology · doi:10.2217/fon-2022-1040 · Cited by 22
Central Nervous System Metastases
Nieblas‐Bedolla, E., Zuccato, J., Kluger, H. M., Zadeh, G. M., & Brastianos, P. K. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.08.004 · Cited by 23
Tan, A. C., Boggs, D. H., Lee, E. Q., Kim, M. M., Mehta, M. P., & Khasraw, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780379 · Cited by 23
“The remaining trials incorporated secondary endpoints assessing intracranial response and/or time to intracranial progression, including trials such as ARROW (pralsetinib) (35) and LIBRETTO-001 (selpercatinib) (36) for RET rearranged NSCLC, HER2CLIMB (tucatinib) (39) for HER2 positive breast cancer and ALKA/ STARTRK-1…”
BackgroundRubovszky, G., Kocsis, J., Boér, K., Chilingirova, N. P., Dank, M., Kahán, Z., Kaidarova, D., Kövér, E., Vertáková-Krakovská, B., Máhr, K., et al. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610383 · Cited by 24
“• Tucatinib plus trastuzumab in combination with capecitabine showed benefits in terms of median PFS and OS in comparison with trastuzumab plus capecitabine in patients who have progressed on trastuzumab, pertuzumab, and TDM1 including patients with brain metastases (128, 129).”
BackgroundCurrent status of precision oncology in adult glioblastoma
Weller, J. M., Potthoff, A., Zeyen, T., Schaub, C., Duffy, C., Schneider, M. B., & Herrlinger, U. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13678 · Cited by 22
Pellerino, A., Soffietti, R., Bruno, F., Manna, R., Muscolino, E., Botta, P., Palmiero, R. A., & Rudà, R. (2022) · Cancers · doi:10.3390/cancers14051192 · Cited by 23
“The scenario is rapidly evolving after the investigation of tucatinib in the HER2CLIMB trial on HER2+ metastatic BC, which displayed superiority in all the planned outcomes, such as PFS, OS, objective response rate [36] and quality of life [37] including in patients with BM [38].”
BackgroundRacial disparities in breast cancer preclinical and clinical models
Clarke, S., Chin, S. N., Dodds, L. V., George, S. H. L., & Badal, S. A. M. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01551-x · Cited by 23
Giugliano, F., Schianca, A. C., Corti, C., Ivanova, M. D., Bianco, N., Dellapasqua, S., Criscitiello, C., Fusco, N., Curigliano, G., & Munzone, E. (2023) · Cancers · doi:10.3390/cancers15051385 · Cited by 23
“Even if the randomized phase II HER2CLIMB enrolled patients who had previously received trastuzumab and T-DM1, the PFS and OS benefits in patients with active or stable brain metastasis suggest its possible use for selected patients in this setting [26].”
BackgroundSelf-citationTargeted Hyperbranched Nanoparticles for Delivery of Doxorubicin in Breast Cancer Brain Metastasis
Lim, M., Fletcher, N. L., Saunus, J. M., Reed, A. E. M., Chittoory, H., Simpson, P. T., Thurecht, K. J., & Lakhani, S. R. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00558 · Cited by 22
Current treatment options for HER2-positive breast cancer patients with brain metastases
Galanti, D., Inno, A., Vecchia, M. L., Borsellino, N., Incorvaia, L., Russo, A. D., & Gori, S. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103329 · Cited by 24
Gao, Y. K., Kuksis, M., Said, B. I., Chehade, R., Kiss, A., Tran, W. T., Sickandar, F., Sahgal, A., Warner, E., Soliman, H., et al. (2021) · The Oncologist · doi:10.1002/onco.13965 · Cited by 21
“Given that HER2-targeted therapies, such as tucatinib [39, 40] and TDM1 [41], have demonstrated activity in the CNS, we are likely to see even better overall and brainspecific outcomes among patients with HER2+ breast cancer BrM over time.”
Schettini, F., Conte, B., Buono, G., Placido, P. D., Parola, S., Griguolo, G., Fabi, A., Bighin, C., Riccardi, F., Cianniello, D., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100099 · Cited by 21
“trastuzumab deruxtecan, margetuximab, tucatinib) have proven to be effective in highly pretreated patients, including those treated with pertuzumab and T-DM1 in an advanced setting and are FDA approved.(48-50) It is possible that these novel drugs might gain a major role in earlier lines, especially in potential antiH…”
BackgroundAnti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
Cicenas, J., & Račienė, A. (2021) · Cancers · doi:10.3390/cancers13050947 · Cited by 21
“The decision was made relying on results from the HER2CLIMB clinical trial (NCT02614794), a study on tucatinib versus placebo in combination with capecitabine and trastuzumab, enrolling 612 patients [13].”
MethodDauccia, C., Agostinetto, E., Arecco, L., Lobo-Martins, S., Gitto, M., Lyon, A. R., López‐Fernández, T., Dent, S. F., Casalino, G., Agarwala, V., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105128 · Cited by 21
Zhang, J., Yu, Y., Lin, Y., Kang, S., Lv, X., Liu, Y., Lin, J., Wang, J., & Song, C. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211006948 · Cited by 23
Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
Ulrich, L., & Okines, A. F. C. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s268451 · Cited by 22
“03).(83) Tucatinib also significantly reduced the risk of intracranial progression by 68% (HR 0.”
BackgroundResultInfluentialSelf-citationCordero, Á., Ramsey, M. D., Kanojia, D., Fares, J., Petrosyan, E., Schwartz, C. W., Burga, R. A., Zhang, P., Rashidi, A., Castro, B. A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2112491119 · Cited by 21
“progression or death was 52% lower in the tucatinib combination group than in the placebo combination group (23).”
InfluentialOptimizing treatment for HER2-positive HR-positive breast cancer
Debien, V., de Azambuja, E., & Piccart, M. J. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102529 · Cited by 23
Lin, N., Kumthekar, P., Sahebjam, S., Ibrahim, N. K., Fung, A., Cheng, A., Nicholas, A., Sussell, J. A., & Pegram, M. D. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00587-2 · Cited by 20
“Newer systemic interventions, including those that improve OS, have become available since the PATRICIA study was conducted 10,16 .”
BackgroundInfluentialSelf-citationMusolino, A., Boggiani, D., Pellegrino, B., Zanoni, D., Sikokis, A., Missale, G., Silini, E. M., Maglietta, G., Frassoldati, A., & Michiara, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102927 · Cited by 20
Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines
Kuroiwa, Y., Nakayama, J., Adachi, C., Inoue, T., Watanabe, S., & Semba, K. (2020) · Cancers · doi:10.3390/cancers12071811 · Cited by 23
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
Floros, K. V., Jacob, S., Kurupi, R., Fairchild, C. K., Hu, B., Puchalapalli, M., Koblinski, J. E., Dozmorov, M. G., Boikos, S. A., Scaltriti, M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03457-6 · Cited by 20
Chilà, G., Guarini, V., Galizia, D., Geuna, E., & Montemurro, F. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s281599 · Cited by 20
“The first, and more obvious, is with the pure HER2-TKI Tucatinib.(40) The HER2CLIMB trial tested the addition of this compound to treatment with trastuzumab and capecitabine in”
BackgroundClinicopathologic features and treatment advances in cancers with HER2 alterations
Cen, S., Liu, Z., Pan, H., & Han, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188605 · Cited by 23
Gión, M., Pérez-García, J. M., Llombart‐Cussac, A., Sampayo-Cordero, M., Cortés, J., & Malfettone, A. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211059587 · Cited by 22
Advances in the Diagnosis and Treatment of Leptomeningeal Disease
Sharma, A., Low, J., & Kumthekar, P. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01198-3 · Cited by 21
Yamamoto, Y., Iwata, H., Taira, N., Masuda, N., Takahashi, M., Yoshinami, T., Ueno, T., Toyama, T., Yamanaka, T., Takano, T., et al. (2022) · Cancer Science · doi:10.1111/cas.15474 · Cited by 21
Bartsch, R., Marhold, M., Garde, J., Gión, M., Ruíz-Borrego, M., Greil, R., Valero, M., Llombart‐Cussac, A., Garcia, J. J., Arumí, M., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00470-x · Cited by 20
“7,8 During the past 5 years, patients given trastuzumab deruxtecan have been shown to have unprecedented intracranial response rates and prolonged disease control, even in the presence of brain metastases.”
InfluentialSelf-citationDormann, C. (2020) · Breast Care · doi:10.1159/000512328 · Cited by 22
Emerging Targeted Therapies for Early Breast Cancer
Schlam, I. M., Tarantino, P., Morganti, S., Lynce, F. C., Trapani, D., Mayer, E. L., Garrido-Castro, A. C., Waks, A., & Tolaney, S. M. (2022) · Drugs · doi:10.1007/s40265-022-01781-5 · Cited by 19
“There is also interest to see if tucatinib can help prevent CNS recurrences, given data in the metastatic setting suggesting robust activity in the CNS [84].”
BackgroundInfluentialKim, I. A., Winter, K. A., Sperduto, P. W., Santos, J. F. D. L., Peereboom, D. M., Ogunleye, T., Boulter, D. J., Fritz, J., Cho, K. H., Shin, K. H., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.07.019 · Cited by 20
Long-term Survival From Breast Cancer Brain Metastases in the Era of Modern Systemic Therapies
Mashiach, E., Alzate, J. D., Vasconcellos, F. D. N., Bernstein, K., Donahue, B. R., Schnurman, Z., Gurewitz, J., Rotman, L. E., Adams, S., Meyers, M. I., et al. (2023) · Neurosurgery · doi:10.1227/neu.0000000000002640 · Cited by 22
“…newer TT can cross the blood-brain barrier and affect BM, and thus, using TT with an SRS maintenance approach holds promise to patients with BCBM. 12 In line with previous studies, we found that patients on chemotherapy alone exhibited 60% increased risk of mortality ( P = .030), whereas those…”
ResultInfluentialUpdates in Treatment of HER2-positive Metastatic Breast Cancer
Avelino, A. R. M., Pulipati, S., Jamouss, K. T., & Bhardwaj, P. V. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01277-2 · Cited by 22
“…pertuzumab, and T-DM1), addition of tucatinib compared to placebo with trastuzumab and capecitabine improved median PFS [7.6 months versus 4.9 months, HR 0.57 (95% CI 0.47 – 0.70); p < 0.00001] and median OS [24.7 months versus 19.2 months, HR 0.73 (95% CI 0.59 – 0.90); p = 0.004) [30, 31].”
InfluentialEstruch, M., Reckzeh, K., Vittori, C., Centio, A., Ali, M., Engelhard, S., Zhao, L., Won, K., Liu, P., Porse, B. T., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01094-0 · Cited by 22
Lyu, X., & Luo, B. (2021) · Cancer Medicine · doi:10.1002/cam4.4326 · Cited by 22
Yan, F., Rinn, K. J., Kullnat, J. A., Wu, A., Ennett, M. D., Scott, E. L., & Kaplan, H. G. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7006 · Cited by 19
Topletz‐Erickson, A. R., Lee, A. J., Rustia, E. L., Sun, H., Mayor, J. G., Abdulrasool, L. I., Walker, L. N., & Endres, C. J. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01144-z · Cited by 19
“The rapid, reversible, and clinically insignificant elevations in serum creatinine that have been observed with tucatinib administration have been shown to result from inhibition of the multidrug and toxin extrusion 1/2-K (MATE1/2-K) transporter by tucatinib, which increases serum creatinine without affecting glomerul…”
BackgroundSelf-citationThe Present and Future of Clinical Management in Metastatic Breast Cancer
Lin, P., & Laliotis, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195891 · Cited by 20
“The efficacy of tucatinib in combination with trastuzumab and capecitabine, was addressed in the phase II HER2CLIMB trial [65,66], leading to approval of this combination in 2020, for patients with advanced or metastatic HER-2+ mBC and have previously received anti-HER-2 based therapies.”
BackgroundIs there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
Schlam, I. M., & Tolaney, S. M. (2021) · Oncotarget · doi:10.18632/oncotarget.27904 · Cited by 19
Lüftner, D., Schneeweiß, A., Hartkopf, A. D., Müller, V., Wöckel, A., Janni, W., Ettl, J., Belleville, E., Schütz, F., Thill, M., et al. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1111-8775 · Cited by 18
“In San Antonio, the results of the HER2Climb study were presented: it involved 612 patients who had all been pretreated with trastuzumab/pertuzumab as well as with T‐DM1 and who had already received a median of 4 lines of therapy [12].”
BackgroundSelf-citationEstruch, M., Vittori, C., Montesinos, T. M., Reckzeh, K., & Theilgaard‐Mönch, K. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.76 · Cited by 25
Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects
Liu, C., Amin, R. N., Shatila, M., Short, N. J., Altan, M., Shah, A. Y., Alhalabi, O., Okhuysen, P. C., Thomas, A. S., & Wang, Y. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04316-3 · Cited by 19
“We take particular interest in GI toxicity, as studies demonstrated TKI-induced diarrhea to occur in 30–90% of patients treated with TKIs, depending on the specific TKI used (Grothey et al., 2012; Motzer et al. 2007; Rini et al. 2011; Leboulluex et al. 2012; Natale et al. 2011; Lee et al. 2012; Shah et al. 2005; Soria…”
BackgroundChe, W., Liu, J., Fu, T., Wang, X., & Lyu, J. (2022) · Current Oncology · doi:10.3390/curroncol29110660 · Cited by 19
“, tucatinib) significantly improved overall survival and progression-free survival of HER2+ breast cancer cases with BMs [51,52].”
BackgroundPalange, A. L., Mascolo, D. D., Ferreira, M. F. M. M., Gawne, P. J., Spanò, R., Felici, A., Bono, L., Moore, T. L., Salerno, M., Armirotti, A., et al. (2023) · Advanced Science · doi:10.1002/advs.202205223 · Cited by 18
HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments
Essâdi, I., Benbrahim, Z., Kaakoua, M., Reverdy, T., Corbaux, P., & Freyer, G. (2023) · Cancers · doi:10.3390/cancers15061738 · Cited by 18
“The efficacy of tucatinib has been documented through the HER2CLIMB trial including a total of 612 patients with HER2-positive MBC, previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine [48].”
BackgroundLi, R., Sant, S. A., Brown, E., Caramia, F., Nikolic, B., Clarke, K. A., Byrne, A., Gonzalez, L. E. L., Savas, P. S., Luen, S. J., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad072 · Cited by 18
Self-citationCost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs
Lam, M. S., Olivier, T., Haslam, A., Tuia, J. E., & Prasad, V. K. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2306 · Cited by 20
Liang, X., Gui, X., Yan, Y., Di, L., Liu, X., Li, H., & Song, G. (2023) · The Oncologist · doi:10.1093/oncolo/oyad228 · Cited by 18
“A few patients were pretreated with trastuzumab plus pertuzumab (22 [9.21%]), or trastuzumab emtansine (T-DM1; 14 [5.86%]; Table 1).”
BackgroundInfluentialCardiotoxicity of Agents Used in Patients With Breast Cancer
Zagami, P., Trapani, D., Nicolò, E., Corti, C., Valenza, C., Criscitiello, C., Curigliano, G., & Carey, L. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00494 · Cited by 21
Self-citationStandard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options
Premji, S., & O'Sullivan, C. C. (2024) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234241234418 · Cited by 21
Abouelenein, M. G., Mohamed, M. B. I., Elsenety, M. M., El-Rashedy, A. A. E., Ghalib, S. H., Mohamed, F. A. E., El‐Ebiary, N. M. A., & Ageeli, A. A. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202301986 · Cited by 18
Trastuzumab-Induced Cardiotoxicity: When and How Much Should We Worry?
Zheng, H., Mahmood, S., Khalique, O. K., & Zhan, H. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00816 · Cited by 19
The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?
Venturini, J., Massaro, G., Lavacchi, D., Rossini, D., Pillozzi, S., Caliman, E., Pellegrini, E., & Antonuzzo, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104515 · Cited by 19
Chan, W., Lam, T., Lam, K. O., Luk, M., Kai-Cheong, R. N., & Kwong, L. W. D. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920953729 · Cited by 18
Crespo, J., Sun, H., Wu, J., Ding, Q.-Q., Tang, G., Robinson, M. K., Chen, H., Şahin, A. A., & Lim, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241775 · Cited by 18
“HER2 contributes to the aggressive features of breast cancers; however, rapid evolution of anti-HER2 therapies, including anti-HER2 antibodies such as trastuzumab [4], pertuzumab [5], T-DM1 [6], and DS-8201 [7] and pan-HER2 inhibitors such as neratinib [8], lapatinib [9], and tucatinib [10], has significantly improved…”
BackgroundRecent updates in systemic therapy of breast cancer: A brief narrative review
Arora, S., & Gogia, A. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_335_20 · Cited by 19
Metadata
- Authors
- Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, E., Bachelot, T., Shachar, S. S., Müller, V., Braga, S., Duhoux, F. P., Greil, R., Cameron, D., Carey, L. A., Curigliano, G., Gelmon, K., Hortobagyi, G., Krop, I., Loibl, S., Pegram, M., Slamon, D., Palanca-Wessels, M. C., Walker, L., Feng, W., & Winer, E. P.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) — both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology–Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center–Jonsson...
- BC Cancer Agency (CA)
- ORCID
- Murthy, Rashmi K.
- Loi, Sherene
- Okines, Alicia
- Hamilton, Erika
- Hurvitz, Sara A.
- Borges, Virginia
- Abramson, Vandana
- Anders, Carey
- Bedard, Philippe L.
- Oliveira, Mafalda
- Jakobsen, Erik
- Bachelot, Thomas
- Shachar, Shlomit S.
- Müller, Volkmar
- Braga, Sofia
- Duhoux, Francois P.
- Greil, Richard
- Cameron, David
- Curigliano, Giuseppe
- Gelmon, Karen
- Krop, Ian
- Loibl, Sibylle
- Pegram, Mark
- Slamon, Dennis
- Palanca-Wessels, M. Corinna
- Feng, Wentao
- Winer, Eric P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 597-609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2995808512
- Cited by
- 1,326
- References
- 29
- Citations by year
- 2026: 118 · 2025: 158 · 2024: 203 · 2023: 197 · 2022: 252 · 2021: 244 · 2020: 152
- FWCI
- 67.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Seattle Genetics
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- tucatinib, HER2-positive metastatic breast cancer, trastuzumab, capecitabine, HER2 tyrosine kinase inhibitor, brain metastases, progression-free survival, overall survival, pertuzumab, trastuzumab emtansine, HER2-targeted therapy, diarrhea, hand-foot syndrome
- MeSH terms
- Trastuzumab, Capecitabine, Progression-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Diarrhea, Double-Blind Method, Female, Humans, Middle Aged, Oxazoles, Protein-Tyrosine Kinases, Pyridines, Quinazolines, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Kaplan-Meier Estimate, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.